These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 37308951)

  • 1. Real-world hepatitis C treatment outcomes and reinfections among people who inject drugs at a needle and syringe program in Stockholm, Sweden.
    Lindqvist K; Thorin Z; Kåberg M
    Harm Reduct J; 2023 Jun; 20(1):72. PubMed ID: 37308951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence, risk factors, treatment uptake and treatment outcome of hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala, Sweden.
    Kågström E; Lannergård A; El Khosht J; Lörelius P; Månflod J; Strömdahl S
    Harm Reduct J; 2023 Jun; 20(1):77. PubMed ID: 37328868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
    Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ
    J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in hepatitis C virus prevalence and incidence among people who inject drugs in the direct acting antiviral era.
    Gahrton C; Navér G; Warnqvist A; Dalgard O; Aleman S; Kåberg M
    Int J Drug Policy; 2024 Jun; 128():104433. PubMed ID: 38703622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive needle and syringe program and opioid agonist therapy reduce HIV and hepatitis c virus acquisition among people who inject drugs in different settings: A pooled analysis of emulated trials.
    van Santen DK; Lodi S; Dietze P; van den Boom W; Hayashi K; Dong H; Cui Z; Maher L; Hickman M; Boyd A; Prins M
    Addiction; 2023 Jun; 118(6):1116-1126. PubMed ID: 36710474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates.
    Lens S; Miralpeix A; Gálvez M; Martró E; González N; Rodríguez-Tajes S; Mariño Z; Saludes V; Reyes-Urueña J; Majó X; Colom J; Forns X
    JHEP Rep; 2022 Dec; 4(12):100580. PubMed ID: 36316992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low Hepatitis C Reinfection Following Direct-acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy.
    Akiyama MJ; Lipsey D; Heo M; Agyemang L; Norton BL; Hidalgo J; Lora K; Litwin AH
    Clin Infect Dis; 2020 Jun; 70(12):2695-2702. PubMed ID: 31346609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs.
    Weir A; McLeod A; Innes H; Valerio H; Aspinall EJ; Goldberg DJ; Barclay ST; Dillon JF; Fox R; Fraser A; Hayes PC; Kennedy N; Mills PR; Stanley AJ; Aitken C; Gunson R; Templeton K; Hunt A; McIntyre P; Hutchinson SJ
    Drug Alcohol Depend; 2016 Aug; 165():53-60. PubMed ID: 27268294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world outcomes of rapid regional hepatitis C virus treatment scale-up among people who inject drugs in Tayside, Scotland.
    Byrne CJ; Beer L; Inglis SK; Robinson E; Radley A; Goldberg DJ; Hickman M; Hutchinson S; Dillon JF
    Aliment Pharmacol Ther; 2022 Mar; 55(5):568-579. PubMed ID: 34877667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units.
    Valencia J; Alvaro-Meca A; Troya J; Cuevas G; Gutiérrez J; Morro A; Alvarez J; Pulido L; Cañamares I; Escobar I; Moreno S; Ryan P
    Int J Drug Policy; 2019 Oct; 72():181-188. PubMed ID: 31253391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.
    Fraser H; Mukandavire C; Martin NK; Goldberg D; Palmateer N; Munro A; Taylor A; Hickman M; Hutchinson S; Vickerman P
    Addiction; 2018 Nov; 113(11):2118-2131. PubMed ID: 29781207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.
    Rossi C; Butt ZA; Wong S; Buxton JA; Islam N; Yu A; Darvishian M; Gilbert M; Wong J; Chapinal N; Binka M; Alvarez M; Tyndall MW; Krajden M; Janjua NZ;
    J Hepatol; 2018 Nov; 69(5):1007-1014. PubMed ID: 30142429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, Norway.
    Midgard H; Ulstein K; Backe Ø; Foshaug T; Sørli H; Vennesland K; Nilssen D; Dahl EH; Finbråten AK; Wüsthoff L; Dalgard O
    Int J Drug Policy; 2021 Oct; 96():103165. PubMed ID: 33642182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A simplified point-of-service model for hepatitis C in people who inject drugs in South Africa.
    Saayman E; Hechter V; Kayuni N; Sonderup MW
    Harm Reduct J; 2023 Mar; 20(1):27. PubMed ID: 36870990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and spontaneous clearance of hepatitis C virus (HCV) in people who inject drugs at the Stockholm Needle Exchange-Importance for HCV elimination.
    Kåberg M; Navér G; Hammarberg A; Weiland O
    J Viral Hepat; 2018 Dec; 25(12):1452-1461. PubMed ID: 29998522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can hepatitis C elimination targets be sustained among people who inject drugs post-2030?
    Lanièce Delaunay C; Godin A; Kronfli N; Panagiotoglou D; Cox J; Alary M; Klein MB; Maheu-Giroux M
    Int J Drug Policy; 2021 Oct; 96():103343. PubMed ID: 34215459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of hepatitis C cure among people who inject drugs treated with directly observed therapy supported by peer case managers in Kenya.
    Akiyama MJ; Riback LR; Nyakowa M; Musyoki H; Lizcano JA; Muller A; Zhang C; Walker JG; Stone J; Vickerman P; Cherutich P; Kurth AE
    Int J Drug Policy; 2023 Mar; 113():103959. PubMed ID: 36758335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
    Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL
    Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data.
    Palmateer NE; McAuley A; Dillon JF; McDonald S; Yeung A; Smith S; Barclay S; Hayes P; Shepherd SJ; Gunson RN; Goldberg DJ; Hickman M; Hutchinson SJ
    Addiction; 2021 Oct; 116(10):2893-2907. PubMed ID: 33651446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.